Novartis' New Blood Pressure Weapon

Tekturna, the first in a class of drugs known as renin inhibitors, is likely to be a blockbuster in the high-stakes, hypertension control game

Editor's note: This is an updated version of a previously published story.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.